In addition, recurrent focal genomic amplification spanning IGF2, WiNTRLINC1, and ASCL2 genes was detected in 9.9% of colorectal carcinomas and 2.7% of stomach adenocarcinomas (Fig. 5b, Supplementary Fig. 14). This evidence concerns the gene ASCL2 and gastric adenocarcinoma.